Clinical trial NCT04212000: Bioavailability of Levoketoconazole and Ketoconazole Tablets
Official title: A Phase 1 Randomized, Open-Label, Two-Period,Two-Sequence Crossover Study to Evaluate the Relative Oral Bioavailability of Levoketoconazole and Ketoconazole Tablets in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Cortendo AB
Sponsor class: INDUSTRY
First posted: 2019-12-26
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This is a phase 1, randomized, open-label, single-dose, two-period, two-sequence crossover study in healthy male and female subjects to evaluate the relative oral bioavailability of levoketoconazole tablets (the test drug) and ketoconazole tablets (the reference drug product).

Detailed description: This is a phase 1, randomized, open-label, single-dose, two-period, two-sequence crossover study in healthy male and female subjects to evaluate the relative oral bioavailability of levoketoconazole tablets (the test drug) and ketoconazole tablets (the reference drug product). Subjects will be randomized to receive a single oral dose of 150 mg levoketoconazole (Study Drug A) or a single oral dose of 200 mg ketoconazole (Study Drug B) in each period.

Eligibility criteria: Inclusion Criteria:

1. 18 to 55 years of age, inclusive, at time of consent.
2. Body mass index (BMI) between 18.0 and 32.0 kg/m2,inclusive.
3. In good general physical health as determined by absence of clinically significant medical history, physical examination findings, vital signs, clinical laboratory evaluations, and ECG measurements.
4. Has not consumed and agrees to abstain from taking any prescription drugs, dietary supplements including vitamins and herbal preparations, or non-prescription drugs for 14 days prior to clinical research unit (CRU) admission, during washout period, and through Follow-Up.
5. Has not consumed alcohol-containing beverages for 3 days prior to CRU admission and agrees not to consume alcohol through Follow-Up.
6. Is a nonsmoker (for at least 3 months) with negative urinary cotinine test at Screening and agrees to abstain from tobacco-and nicotine-containing products for the duration of the study.

Exclusion Criteria:

1. Evidence of any out-of-normal-range laboratory value at Screening that has not been reviewed, approved, and documented as Not Clinically Significant by the Investigator.
2. Concurrent medical illness that would interfere with the conduct of the study in the opinion of the Investigator.
3. History or presence of clinically significant cardiovascular, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic, psychiatric, renal, hepatic, chronic respiratory, or gastrointestinal disease as judged by the Investigator.
4. Positive urine drug screen for drugs-of-abuse, including cocaine, tetrahydrocannabinol, opioids, benzodiazepines, amphetamines, and barbiturates,and/or positive urine screen for alcohol at Screening and CRU admission.
5. Treatment with an investigational drug within the longer of 30 days or five half-lives of the investigational drug preceding the first dose of study drug.
6. Positive for HIV, hepatitis B, and/or hepatitis C on Screening assessments.
7. Acute illness within 7 days of CRU admission.
8. Donated plasma within 7 days of drug administration.
9. Donated 1 or more pints of blood (or equivalent blood loss) within 30 days prior to drug administration.
10. History of caffeine consumption exceeding 8 cups coffee/day within 14 days prior to first dose, or consumption of any caffeine-or chocolate-containing products for 3 days prior to CRU admission each week.
11. Female subjects who are pregnant or lactating.
12. Males with hemoglobin less than 12.0 g/dL at Screening or CRU admission; Females with hemoglobin less than 11.0 g/dL at Screening or CRU admission
13. Had difficulties with swallowing whole tablets.
14. Body habitus preventing repeated venipuncture as required by protocol.

Primary outcomes:
measure: Ratio of geometric least squares means for AUClast of plasma levoketoconazole (2S,4R-ketoconazole)
timeFrame: 24 hours
measure: Ratio of geometric least squares means for AUCinf of plasma levoketoconazole (2S,4R-ketoconazole)
timeFrame: 24 hours
measure: Ratio of geometric least squares means for Cmax of plasma levoketoconazole (2S,4R-ketoconazole)
timeFrame: 24 hours
Secondary outcomes:
measure: Terminal phase rate constant (λz)
timeFrame: 24 hours
measure: Time to Maximum Plasma concentration (Tmax)
timeFrame: 24 hours
measure: Lag-time (Tlag)
timeFrame: 24 hours
measure: Apparent systemic clearance (CL/F)
timeFrame: 24 hours
measure: The percentage of area under the plasma concentration-time curve extrapolated from time 0 to infinity as a percentage of total AUC (%AUCext)
timeFrame: 24 hours
measure: Volume of Distribution (Vz/F)
timeFrame: 24 hours
measure: Elimination half-life (T1/2)
timeFrame: 24 hours
measure: Incidence of adverse events (AEs)
timeFrame: 35 days
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: Pharmaceutical Research Associates, Inc.
state: Utah
Study officials:
affiliation: Cortendo AB
name: Xavier Valencia, MD
role: STUDY_DIRECTOR
References: